Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Innovative Medical

Status and phase: Completed; Phase 4

Conditions: Glaucoma

Treatments: Drug: Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%

Study type: Interventional

Funder types: Industry

Identifiers

NCT00348023

5179

Details and patient eligibility

About

Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• · Male or female > 18 years of age

  • Diagnosis of primary open-angle glaucoma or ocular hypertension
  • Untreated IOP > 18 mm Hg in each eye at the baseline evaluation
  • Ability to provide informed consent and likely to complete all study visits

Exclusion criteria

• · Known contraindication to bimatoprost, travoprost, timolol, or any component of any study medication

  • Uncontrolled systemic disease
  • Active ocular disease other than POAG or ocular hypertension
  • Required use of ocular medications other than the study medications during the study (intermittent use of OTC artificial tear products will be permitted)
  • History of intraocular surgery within the last 3 months
  • Patient must not have discontinued use of any medication included in this study in the past for reasons of efficacy or intolerance